SG&A Expense (TTM) Chart

Historical SG&A Expense (TTM) Data

View and export this data back to 2017. Start Trial.
Date Value
June 30, 2026 863.63M
March 31, 2026 781.86M
December 31, 2025 706.07M
September 30, 2025 658.40M
June 30, 2025 624.77M
March 31, 2025 577.25M
December 31, 2024 545.06M
September 30, 2024 505.21M
June 30, 2024 463.31M
March 31, 2024 453.54M
December 31, 2023 451.03M
September 30, 2023 453.55M
June 30, 2023 469.93M
March 31, 2023 474.65M
December 31, 2022 463.78M
September 30, 2022 444.35M
June 30, 2022 423.14M
March 31, 2022 401.95M
December 31, 2021 398.52M
Date Value
September 30, 2021 399.44M
June 30, 2021 390.55M
March 31, 2021 356.66M
December 31, 2020 299.28M
September 30, 2020 239.64M
June 30, 2020 183.49M
March 31, 2020 154.17M
December 31, 2019 139.73M
September 30, 2019 128.25M
June 30, 2019 114.60M
March 31, 2019 102.29M
December 31, 2018 89.66M
September 30, 2018 78.35M
June 30, 2018 80.66M
March 31, 2018 74.69M
December 31, 2017 69.27M
September 30, 2017 50.92M
June 30, 2017 27.02M
March 31, 2017 12.42M

SG&A Expense (TTM) Range, Past 5 Years

View SG&A Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (TTM) Benchmarks

View SG&A Expense (TTM) Benchmarks
Start Trial
Natera, Inc. 1.255B
Quest Diagnostics, Inc. 2.038B
Labcorp Holdings, Inc. 2.219B
OPKO Health, Inc. 205.85M
Psychemedics Corp. --